The answer: Four distinct smokeless tobacco and nicotine delivery products, each with different delivery mechanisms, different risk profiles, and different roles in the tobacco industry’s strategy of maintaining nicotine markets as smoking declines.

Chewing tobacco

Loose leaf, plug, or twist tobacco placed between the cheek and gum, held there for extended periods while nicotine is absorbed through the oral mucosa. The user periodically spits the tobacco-laden saliva, producing the characteristic spitting behavior associated with tobacco chewing.

In India, chewing tobacco exists in multiple forms like plain tobacco leaf, khaini (tobacco mixed with lime), zarda (tobacco mixed with lime and spices), and as an ingredient in gutka and paan masala.

Health profile: Direct carcinogen contact with oral mucosa produces high rates of oral cancer, leukoplakia, and oral submucous fibrosis. Nicotine absorbed continuously through oral mucosa produces deep physical dependence, often deeper than cigarette dependence due to the sustained delivery model. Cardiovascular risk from nicotine equivalent to smoking.

Snuff tobacco

Dry snuff: Finely ground tobacco inhaled through the nose- the traditional European form, now largely replaced by other products. Delivers nicotine through nasal mucosa. Produces nasal mucosal damage, elevated nasal and pharyngeal cancer risk, and nicotine dependence.

Moist snuff (snus): A portion of moist tobacco placed under the upper lip- the Scandinavian form that has become the subject of the harm reduction debate. Delivers nicotine through oral mucosa without combustion, spitting, or nasal inhalation. Produces significantly lower lung cancer risk than cigarettes- the basis of Sweden’s dramatically lower smoking-related mortality, cited in harm reduction advocacy. Still produces oral cancer risk, permanent gum recession, nicotine dependence, and cardiovascular risk through nicotine delivery.

Naswar: A moist tobacco product used in Pakistan, Afghanistan, and parts of India typically placed under the tongue or in the lower lip. Contains tobacco, lime, ash, and various additives. Produces oral cancer risk comparable to other smokeless tobacco products and significant nicotine dependence.

Dissolvable tobacco

Compressed tobacco in the form of strips, sticks, orbs, or lozenges that dissolve in the mouth, releasing nicotine through oral mucosal absorption without spitting. Designed to be used discreetly in smoke-free environments- the product that produces no visible evidence of tobacco use.

Dissolvable tobacco products were developed and marketed primarily in the United States and have not achieved significant market penetration in India. They represent the tobacco industry’s attempt to create a smokeless, spit-free product that circumvents smoke-free environment restrictions.

Health profile: Delivers nicotine and carcinogens through oral mucosal absorption. Oral cancer risk from carcinogen contact. Cardiovascular risk from nicotine. Significant dependence potential from sustained oral nicotine delivery. The discrete, concealable form makes them particularly concerning for youth initiation and use in school environments.

Nicotine toothpicks

Wood or bamboo toothpicks infused with nicotine (and sometimes flavoring) held in the mouth to deliver low-level nicotine through oral mucosal absorption. Positioned as a smoking cessation aid or a discreet nicotine delivery method for situations where smoking or vaping is not possible.

Not currently regulated as pharmaceutical nicotine replacement therapy in most markets, existing in a regulatory gap between tobacco products and cessation aids. Available online and in some markets without the safety testing required of pharmaceutical NRT.

Health profile: The nicotine delivery from toothpicks is typically lower than other tobacco products, but the regulatory gap means nicotine content is not consistently verified or standardized. Dependence potential exists from any consistent nicotine delivery source. The oral wood or bamboo contact adds a mucosal irritant independent of the nicotine.

The industry strategy underlying all of these

Each of these products represents the tobacco industry’s response to the same strategic challenge: how to maintain nicotine markets as combusted tobacco becomes increasingly restricted, stigmatized, and regulated.

The industry’s internal documents confirm a consistent strategy- develop products that deliver nicotine through non-combusted routes, position them as reduced-harm alternatives to cigarettes, exploit regulatory gaps that treat them differently from cigarettes, and market them to both existing smokers seeking alternatives and new users who would not have initiated with cigarettes.

The harm reduction argument has legitimate evidence behind it for some products in some populations. The industry’s deployment of harm reduction arguments across all smokeless products, regardless of evidence, represents a strategic use of legitimate science to protect nicotine markets broadly.

The one thing to hold onto

Every product on this list delivers nicotine (the molecule that produces dependence) through a different route.

Different routes produce different cancer risk profiles. None produce zero cancer risk. None produce zero dependence risk.

The product that removes combustion removes the largest single source of tobacco-related mortality. It does not remove the addiction, and the addiction is what drives continued exposure to whatever harm the delivery mechanism produces.

Cignix is India’s neural circuit-based smoking cessation platform. The Cignix Protocol works with the biology of how smoking is learned and how it is unlearned. The entry point is the Smoking Immunity Meter at learn.cignix.com/user/sim. Visit cignix.com.